Amantadine and memantine are in clinical use for the treatment of neurodegenerative diseases such as M. Parkinson and dementia syndrome. In order to contribute to the understanding of the interaction of these uncompetitive NMDA-antagonists with the dopaminergic system in the striatum, the pharmacokinetics and the effects of amantadine and memantine on the dopaminergic system were examined in a microdialysis study in anaesthetized rats. Both substances achieved extracellular fluid concentrations in the striatum known to block NMDA receptors, supporting the assumption that NMDA receptor antagonism is their primary mechanism of action. Both, memantine, and to a lesser degree, amantadine induce a modest dopamine overflow not paralleled by HVA or DOPAC. The small increase in dopamine overflow cannot add substantially to the drugs' action and may be generated indirectly via their NMDA-antagonistic properties.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Efficacy and Safety of Memantine for Children and Adults With ADHD With a Focus on Glutamate-Dopamine Regulation: A Systematic Review.
J Clin Psychiatry
December 2024
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Pharmacotherapy plays a crucial role in treating attention-deficit/ hyperactivity disorder (ADHD). However, current medications for ADHD have limitations and potential adverse effects. Glutamate, a neurotransmitter that directly and indirectly modulates dopamine neurotransmission, is considered a new therapeutic target for ADHD.
View Article and Find Full Text PDFMemantine/Rosuvastatin Therapy Abrogates Cognitive and Hippocampal Injury in an Experimental Model of Alzheimer's Disease in Rats: Role of TGF-β1/Smad Signaling Pathway and Amyloid-β Clearance.
J Neuroimmune Pharmacol
December 2024
Department of Pharmacology and Toxicology, PharmD Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder of complex pathogenesis and multiple interacting signaling pathways where amyloidal-β protein (Aβ) clearance plays a crucial role in cognitive decline. Herein, the current study investigated the possible modulatory effects of memantine/ rosuvastatin therapy on TGF-β1/p-Smad/p21 signaling pathway and their correlation to the blood brain barrier transporters involved in Aβ-clearance and microRNAs as a novel molecular mechanism in AD treatment. AD was induced by a single intracerebroventricular streptozotocin injection (ICV-STZ, 3 mg/kg) in rats and drug therapy was continued for 28 days after AD induction.
View Article and Find Full Text PDFMemantine Alleviates PTSD-like Symptoms and Improves Dendritic Arborization through Modulation of the HPA Axis and Neuroinflammation in Rats.
Neurochem Res
December 2024
Laboratory of Molecular NeuroTherapeutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Uttar Pradesh (UP), 226002, India.
Post-traumatic stress disorder (PTSD) poses significant neurological and psychiatric challenges. Investigations into the glutamatergic system, particularly the N-methyl-D-aspartate (NMDA) receptor, are crucial for understanding PTSD mechanisms. This study aimed to evaluate the therapeutic potential of the non-competitive NMDA receptor antagonist memantine in mitigating PTSD symptoms and to explore its underlying cellular and molecular impacts.
View Article and Find Full Text PDFTaste Masking Study of Cocoa Butter Fast Melt Tablet (FMT) Formulations Containing Memantine Hydrochloride.
Int J Pharm Compd
December 2024
Shenkang Education Technology, Shanghai, China.
Article Synopsis
- - The Fast Melt Tablet (FMT) is a new type of quickly dissolving tablet that uses cocoa butter to melt at body temperature, enhancing its effectiveness when taken orally.
- - The study aimed to improve the taste of FMT containing memantine hydrochloride by using artificial sweeteners like aspartame and acesulfame K; six formulations were tested to find the best flavor masking.
- - Formulation T7, using 30mg of aspartame, was found to effectively mask the bitter taste and has desirable properties for commercialization, showing potential as an easy-to-take treatment for Alzheimer's disease.
onitoring drug fficacy through ulti-mics esearch initiative in lzheimer's isease (MEMORI-AD): A protocol for a multisite exploratory prospective cohort study on the drug response-related clinical, genetic, microbial and metabolomic signatures in Filipino patients with Alzheimer's disease.
BMJ Open
November 2024
Mutli-Omics Research Program for Health, University of the Philippines Manila College of Medicine, Manila, Metro Manila, Philippines.
Introduction: Dementia is one of the leading causes of disability among older people aged 60 years and above, with majority eventually being diagnosed with Alzheimer's disease (AD). Pharmacological agents approved for dementia include acetylcholinesterase enzyme (AChE) inhibitors like rivastigmine, donepezil and galantamine and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine, prescribed as monotherapy or in combination with each other, depending on the severity of disease. There is currently no available study demonstrating the clinical response to these drugs for AD in the Filipino population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!